Research on the effects of stem cell source and patient age on transplantation outcomes

December 08, 2008

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes will be explored at a press conference taking place on Sunday, December 7, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Preliminary results from a study examining a specialized technique for increasing the presence of stem cells in cord blood for transplantation will also be shared during the press conference.

"For years, stem cell transplants have been a standard treatment option for many blood cancers and other hematologic conditions," said Armand Keating, MD, moderator of the press conference and Director, Division of Hematology, and Professor of Medicine at the University of Toronto, Ontario, Canada. "The results of these studies add to the growing body of knowledge about the best regimens available to help produce durable responses and prolonged survival in many groups of patients."

Blood cancers - leukemia, lymphoma, and myeloma - are typically treated with a combination of treatments including chemotherapy, biological therapy, radiation therapy, and stem cell transplantation. Stem cell transplantation is the process by which blood stem cells are collected from a donor, or from the patient prior to chemotherapy, and then infused into the patient after treatment. The transplanted stem cells travel to the bone marrow and begin to produce new blood cells, replacing those that are destroyed as a side effect of chemotherapy. Stem cell transplants are categorized by the source of the stem cells (bone marrow, peripheral blood, or cord blood) and by their origin - autologous (from the patient) or allogeneic (from a donor).

Effect of Stem Cell Source on Transplant Outcomes in Adults With Acute Leukemia: A Comparison of Unrelated Bone Marrow, Peripheral Blood, and Cord Blood [Abstract #151]
Mary Eapen, MBBS, the Center for International Blood and Marrow Transplantation along with the European Group for Blood and Marrow Transplantation and the New York Blood Center

In the absence of a matched sibling donor, the first choice for stem cell transplantation for patients with acute leukemia is an unrelated adult donor whose tissue type matches that of the patient. However, when such a donor is not available, the researchers of this study found that mismatched unrelated cord blood transplants were a suitable alternative to mismatched bone marrow or peripheral blood transplants because cord blood is readily available, making it an ideal option when transplantation is needed urgently.

For successful transplantation, bone marrow and peripheral blood donors are examined for genetic compatibility with the patient by comparing their human leukocyte antigens (HLAs). Current estimates from the National Marrow Donor Program donor registry suggest that the probability of finding a matched unrelated adult donor is relatively low (51 percent for Caucasians, 30 percent for Hispanics, 20 percent for Asians, and 17 percent for African Americans).

Cord blood donated to public cord blood banks can be an alternative source of stem cells for patients who need a transplant but cannot find a matched adult donor. The matching requirements for cord blood are not as strict as for bone marrow or peripheral blood because cord blood cells are immunologically immature and therefore more tolerant to mismatching.

The purpose of this study was to determine the efficacy of three types of stem cell sources: bone marrow, peripheral blood, and cord blood. Study results were based on an analysis of the outcomes of 1,240 adults with acute leukemia (707 patients with acute myeloid leukemia and 533 patients with acute lymphocytic leukemia) from 2002 to 2006. Of those patients who received a bone marrow stem cell transplant, 243 were matched at eight out of eight possible HLA loci and 111 were matched at seven HLA loci. In those receiving a peripheral blood stem cell transplant, 518 were matched at eight HLA loci and 210 at seven HLA loci. In those receiving cord blood transplants, 28 were matched at five or six HLA loci and 110 matched at four HLA loci.

The study found that there were fewer transplant-related deaths for matched peripheral blood and bone marrow transplants (27 percent and 26 percent, respectively) than as for mismatched peripheral blood, bone marrow, and cord blood transplants (42 percent, 37 percent, and 41 percent, respectively). Leukemia-free survival (LFS) and overall survival (OS) were highest after transplantation of matched peripheral blood (LFS: 43 percent; OS: 45 percent) and bone marrow (LFS: 46 percent; OS: 48 percent). These rates were lower after transplantation of mismatched peripheral blood (LFS: 33 percent; OS: 36 percent), bone marrow (LFS: 34 percent; OS: 38 percent), and cord blood (LFS: 33 percent; OS: 35 percent). Importantly, rates of transplant-related deaths, leukemia-free survival, and overall survival for the three types of mismatched transplants were similar even though cord blood transplants were mismatched at more HLA loci.

Notch-Mediated Expansion of Human Cord Blood Progenitor Cells Results in Rapid Myeloid Reconstitution in Vivo Following Myeloablative Cord Blood Transplantation [Abstract #212]
Colleen Delaney, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

This phase I study found that cord blood that is cultured to increase the number of CD34+ stem cells prior to transplantation helped to decrease the time to engraftment in patients with acute myeloid leukemia.

Cord blood is a valuable source of hematopoietic stem cells as it has a higher concentration of these cells than is normally found in adult blood. However, as only a small quantity of blood can typically be obtained from an umbilical cord, resulting in fewer available stem cells for transplantation, researchers have been investigating novel methods to expand the number of stem cells available from cord blood to help increase the success rates of cord blood stem cell transplants.

The objective of this study is to evaluate the safety and potential efficacy of giving increased numbers of cord blood progenitor cells that have been generated through a novel methodology whereby CD34+ cord blood progenitor cells are cultured prior to infusion to rapidly multiply in order to decrease the time required for the transplanted cells to engraft and begin production of healthy blood cells.

A total of six patients with acute myeloid leukemia were treated with a transplantation-preparation regimen of cytoxan (120 mg/kg), fludarabine (75 mg/m2), and TBI (1320 cGy), followed one day later by an infusion of one unit of non-cultured cord blood and one unit of cord blood that had been CD34+ enriched and cultured for 16 days. The non-cultured unit was given to provide long-term repopulating stem cells that had not been previously manipulated, while the goal of the expanded unit was to provide cells capable of rapid myeloid recovery.

To achieve best results, cord blood units that most closely genetically matched the patient were selected for transfusion. All non-cultured cord blood stem cells were matched for four out of six alleles for each patient. For the cultured cord blood cells, two patients received a five-out-of-six allele match and four patients received a four-out-of-six allele match. There was an average CD34+ increase of 160 (range 41 to 382), meaning that for every one CD34+ cell, there were 160 CD34+ cells after the culture, with an average total nucleated cell fold increase of 660 (range 146 to 1496). A control group of 17 patients underwent an identical transplant regimen, but received two non-cultured cord blood units.

A relatively rapid engraftment time, averaging 14 days, was observed in the six patients in the experimental group compared with 25 days for the patients in the control group. The contribution of the expanded and non-cultured cord blood cells was determined by a DNA-based assay beginning seven days following the transplant. In the five patients with early engraftment, the engrafted cells present at day seven were derived almost entirely from the cultured unit. Persistent contribution to engraftment from the cultured cells was noted in two patients. One patient had persistent contribution from the cultured cells through 280 days post-transplant that was no longer noticeable at one year, and the second patient continued to demonstrate contribution from the cultured cells at 180 days post-transplant. One patient died on day 462 from a rare complication of myelitis (inflammation of the spinal cord) caused by the varicella-zoster virus, while all other patients were still in remission.

Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients With AML and MDS: Results From the Center for International Blood and Marrow Transplant Research (CIBMTR) [Abstract #346]
Sergio Giralt, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX

This study found that the outcomes of adults over the age of 65 undergoing allogeneic stem cell transplantation for the treatment of acute myeloid leukemia and myelodysplastic syndromes were similar to younger adults even after adjusting for multiple risk factors. The researchers concluded that age alone should not be a limiting factor for proceeding to allogeneic stem cell transplantation in these patients.

While stem cell transplantation remains one of the best treatment options for increasing overall survival and a possible cure for patients with acute myeloid leukemia and myelodysplastic syndromes, transplants generally are not given to patients over the age of 65 because of concerns about extreme toxicity and poor outcomes. Over the past few years, non-myeloablative transplants that require smaller and safer doses of chemotherapy and radiation have allowed stem cell transplants to be conducted in older individuals or other patients considered too weak to withstand conventional stem cell treatment regimens.

To better study age as a predictor of outcome in patients receiving stem cell transplants, data from the Center for International Blood and Marrow Transplant Research (CIBMTR) on 565 patients with acute myeloid leukemia and 551 patients with myelodysplastic syndromes were retrospectively analyzed for transplant-related mortality, engraftment, incidence of acute and chronic graft-versus-host disease, leukemia-free survival, and overall survival. Outcome data gathered from 1995 to 2005 were stratified into four groups by patient age for comparison: ages 40 to 54, 54 to 59, 60 to 64, and 65 and older.

The analysis found that there was no statistically significant difference in transplant-related mortality across age groups, and no overall difference in the occurrence of acute graft-versus-host disease (31-35 percent at 100 days) or chronic graft-versus-host disease (36-53 percent at two years). Rates of relapse were similar across all age groups (29-30 percent at three years). Additionally, no statistically significant impact of age was found for transplant-related mortality, leukemia-free survival, or overall survival. Type of disease and disease status at transplant were significant risk factors for leukemia-free survival and overall survival at one year and for transplant-related mortality and relapse at two years. Patients' general health and degree of tissue-type match between recipient and donor were also significant at two years for nearly all outcomes.

American Society of Hematology

---

---

	The Miracle Cure - A closer look inside the cord blood stem cell industry (BloodBanker.com Investigative Reports) by BloodBanker.com Have you ever thought a cord blood of a newborn baby can save a life? No one knew it until 1980. It was in this year when a group of scientists found a number of similarities between human cord blood and bone marrow. Three years later, an important confirmation was made and it's suggested cord blood stem cells were good alternative for bone marrow in transplantation. Hundreds of people in the world who are diagnosed with deadly diseases such as leukemia and brain cancer were given a chance to live normally and perform their everyday routine without feeling pain. A cord blood transplant save their lives. However, it's still inevitable some groups create contrasting issues about this miracle cure. They have questions and this book provides you the answers!
	Mercury levels in cord blood and meconium of healthy newborns and venous blood of their mothers: Clinical, prospective cohort study [An article from: Science of the Total Environment, The] by E. Unuvar (Author), H. Ahmadov (Author), A.R. Kiziler (Author), B. Aydemir (Author), T (Author) This digital document is a journal article from Science of the Total Environment, The, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Objectives: The purpose of this study is to investigate the chronic mercury intoxication in pregnant women and newborns living in Istanbul, Turkey. Methods: The research was carried out as a prospective with 143 pregnant women and their newborns. Venous blood from the mother, cord blood from the neonate, and meconium were collected for mercury analysis. Frequency of fish and vegetable-eating and the number of teeth filled were investigated. Analyses were made in cold vapor Atomic Absorption...
	The Blood Cord Short Story. The human city of Pald was once, briefly, free, but it is free no longer. Magic of all kinds is outlawed, and people live by their wits, connections, and honor. Fat Willug is a man with a secret that too many people know. When he is kidnapped and poisoned by a wealthy man's personal doctor, he has one day to recover a stolen--but forbidden--item to earn an antidote. But will that be enough time to puzzle out who stole the enchanted blood cord and return it?
	The Blood Sugar Solution: The UltraHealthy Program for Losing Weight, Preventing Disease, and Feeling Great Now! by Mark Hyman (Author) In THE BLOOD SUGAR SOLUTION, Dr. Mark Hyman reveals that the secret solution to losing weight and preventing not just diabetes but also heart disease, stroke, dementia, and cancer is balanced insulin levels. Dr. Hyman describes the seven keys to achieving wellness-nutrition, hormones, inflammation, digestion, detoxification, energy metabolism, and a calm mind-and explains his revolutionary six-week healthy-living program. With advice on diet, green living, supplements and medication, exercise, and personalizing the plan for optimal results, the book also teaches readers how to maintain lifelong health. Groundbreaking and timely, THE BLOOD SUGAR SOLUTION is the fastest way to lose weight, prevent disease, and feel better than ever.
	Frontiers of Cord Blood Science by Niranjan Bhattacharya (Editor), Phillip Stubblefield (Editor) Cord blood is a significant source of hematopoietic stem and progenitor cells for the treatment of blood and genetic disorders. Cord blood is also an alternative to embryos as a source of tissue for regenerative medicine. Cells from cord blood have been shown to transdifferentiate into nonhematopoietic cells, including those of the brain, heart, liver, pancreas, bone, and cartilage, in tissue culture and in animal systems. Recently it has been demonstrated that both cardiac and glial cell differentiation of cord blood donor cells occurred in recipients of unrelated donor cord blood transplantation as part of a treatment regime for Krabbe disease and Sanfilippo syndrome. These observations raise the possibility that cord blood may serve as a source of cells to facilitate tissue repair and...
	Umbilical Cord Blood: A Future for Regenerative Medicine by Suzanne Kadereit (Author), Suzanne Kadereit (Editor), Gerald Udolph (Editor) Umbilical cord blood, previously discarded, has emerged as a new source of stem cells for hematologic reconstitution, bone marrow failures and other hematologic deficiencies. It has become increasingly clear that umbilical cord tissue contains unique stem cells of great potential for regenerative medicine. Importantly, umbilical cord blood is abundant, can be banked and transported with ease, and thus has an indisputable potential for future regenerative therapies. Driven by a massive interest for regenerative medicine and ethically acceptable stem cell sources, the scientific literature on umbilical cord stem cells has exploded. This book provides a consolidated overview of basic, translational as well as clinical research in academic institutions and industry, on hematopoietic and...
	Cord Blood Characteristics: Role in Stem Cell Transplantation by Shara Cohen (Editor), Elaine Gluckman (Editor), Pablo Rubenstein (Editor), J. Alejandro Madrigal (Editor) The use of cord blood as a source of haematopoietic stem cell transplantation has steadily increased since the first cord blood transplant 11 years ago. This text reviews the molecular and cellular biology of cord blood, the collection and processing of cord blood units, the clinical potential of ex vivo expansion, and concludes with discussion of cord blood banking and matching, and the ethical and legal issues related to blood cell therapy and transplantation.
	Cord of Blood: Possession and the Making of Voodoo (Anthropology, Culture and Society) by Nadia Lovell (Author) The relationship between human beings and their gods lies at the centre of all questions of identity, individual and collective. Nadia Lovell examines how religious feelings reflect notions of personhood and belonging, and how religious involvement can transform gender relations, by focusing on cults of Vodhun (voodoo) possession among the Watchi in Southern Togo. Using this detailed ethnographic study as a point of departure she offers a fascinating insight into the complex interplay between religion, gender, ethnography and globalisation.Lovell argues that the relationship of men and women to the Vodhun is one of mutual dependency: on the one hand human beings will gods to exist; on the other hand, gods embody themselves in human beings, especially women, through possession. Possession,...
	Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program by Committee on Establishing a National Cord Blood Stem Cell Bank Program (Author), Emily Ann Meyer (Editor), Kathi Hanna (Editor), Kristine Gebbie (Editor) With the potential for self-renewal and differentiation, the possibilities for stem cells are enormous. One specific type of stem cell, the hematopoietic progenitor cell (HPC), which is derived from umbilical cord blood (as well as adult bone marrow and mobilized peripheral blood), holds particular promise. To make the most of these HPCs, the Institute of Medicine was asked to consider the optimal structure for a national cord blood program and to address pertinent issues related to maximizing the potential of stem cell technology. "Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program" examines: the role of cord blood in stem cell transplantation; the current status of blood banks already in existence; the optimal structure for the cord blood program; the current use...
	Blood-Spinal Cord and Brain Barriers in Health and Disease by Hari Shanker Sharma (Author) Recent research into the anatomy and pathophysiology of the blood-brain and blood-spinal cord barriers suggests that a breakdown in these barriers can result in several diseases affecting the central nervous system (CNS). This book presents new findings in the area of blood-brain barrier research that suggest barriers play important roles in health and disease conditions. It also discusses the development of new drugs that can modulate the barrier function in the CNS and may provide new approaches to treating neurological diseases such as Alzheimer's disease and other motor neuron diseases, as well as spinal cord trauma. Key Features * Presents the recent progress made in the research on the blood-brain and spinal cord barrier *...